Elacestrant Reinforces Its Role in the Real-World Management of ESR1-Mutated Metastatic Breast Cancer
Highlights
Recent real-world data confirms that elacestrant, the first-in-class oral selective estrogen receptor degrader (SERD), provides a clinically meaningful median time to next treatment (mTTNT) of 7.9 months in patients with ESR1-mutated metastatic breast cancer (mBC).
The efficacy was particularly pronounced in patients with no prior fulvestrant exposure, reaching a mTTNT of 12.9 months, suggesting a significant advantage in earlier endocrine sequencing.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.